Shares of Sun Pharma: Jefferies anticipates solid growth following a recent acquisition
Jefferies said in a note that Dr. Maurice Raycroft, Ph.D., the analyst, offered insights on the positioning of Concert’s lead drug Deuruxolitinib for treating alopecia areata. Jefferies shared its key takeaways from the call with the US analyst from Jefferies regarding Concert Pharma’s acquisition up until its recent acquisition by Sun Pharma. “He discussed potential […]
Shares of Sun Pharma: Jefferies anticipates solid growth following a recent acquisition Read More »